Takeda swoops in and scoops up a cell therapy startup in buyout deal, expanding oncology pipeline
A little more than 4 years after Takeda stepped in to help bankroll the T cell startup GammaDelta Therapeutics with a cool $100 million injection, the global pharma player is getting off the sidelines and buying the biotech for itself.
Takeda execs said Wednesday that they will “obtain GammaDelta’s allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy platforms, which includes both blood-derived and tissue-derived platforms, in addition to early-stage cell therapy programs.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,200+ biopharma pros reading Endpoints daily — and it's free.